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Abstract
Background: Several studies have suggested that the activity of the prefrontal cortex (PFC) and the dopamine
(DA) release in the striatum has an inverse relationship. One would attribute this relationship primarily to the
circuitry comprised of the glutamatergic projection from the PFC to the striatum and the GABAergic projection
from the striatum to the midbrain DA nucleus. However, this circuitry has not characterized satisfactorily yet, so
that no quantitative analysis has ever been made on the activities of the PFC and the striatum and also the DA
release in the striatum.
Methods: In this study, a system dynamics model of the corticostriatal system with dopaminergic innervations is
constructed to describe the relationships between the activities of the PFC and the striatum and the DA release in
the striatum. By taking published receptor imaging data from schizophrenia patients and healthy subjects into this
model, this article analyzes the effects of striatal D2 receptor activation on the balance of the activity and
neurotransmission in the frontostriatal system of schizophrenic patients in comparison with healthy controls.
Results: The model predicts that the suppressive effect by D2 receptors at the terminals of the glutamatergic
afferents to the striatum from the PFC enhances the hypofrontality-induced elevation of striatal DA release by at
most 83%. The occupancy-based estimation of the ‘optimum’ D2 receptor occupancy by antipsychotic drugs is
52%. This study further predicts that patients with lower PFC activity tend to have greater improvement of positive
symptoms following antipsychotic medication.
Conclusion: This model-based parametric study would be useful for system-level analysis of the brains with
psychiatric diseases. It will be able to make reliable prediction of clinical outcome when sufficient data will be
available.
Background
Patients with schizophrenia show hypofrontality, which
has been suggested to be responsible for cognitive
impairment and negative symptoms [1-9]. Hypofrontal-
ity is observed even in prodromal stages of schizophre-
nia, indicating that hypofrontality itself is not sufficient
for the onset of symptoms of schizophrenia but is a
high-risk or vulnerability marker [10-12]. Therefore,
hypofrontality would be a trait-like abnormality that
underlies schizophrenia. On the other hand, hyperactiva-
tion of the dorsolateral prefrontal cortex (DLPFC) has
often been observed during performing a working mem-
ory task [13-15]. The occurrence of hyperactivation of
the DLPFC seems to be dependent on an intrinsic brain
state as well as task performance and subjective efforts
so that the observation has not necessarily been consis-
tent or reproducible. A recent computational analysis of
the DLPFC circuit dynamics suggests that the DLPFC
circuit tends to be unstable under cortical hypodopami-
nergic conditions. This could lead to state-dependent
variability of DLPFC activation that is considered to be
much larger than mere individual differences [16]. Being
consistent with this, schizophrenia patients showed
much lower test-retest reliability than normal subjects
in the working memory activation of the DLPFC, intra-
parietal sulcus, and insula [17]. It would, therefore, be
possible to distinguish seemingly inconsistent hyperacti-
vation of the DLPFC, a state-dependent phenomenon,
from trait-like hypofrontality.
The activity of the PFC would have an influence on
the activity of the striatum via the glutamatergic
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any medium, provided the original work is properly cited.frontostriatal projection. Hypofrontality would then lead
to a decrease in the activity of the striatal medium spiny
neurons (MSNs). This would increase the DA concen-
tration in the striatum due to the disinhibition of the
DA neurons to which the MSNs send axons. As a con-
sequence, the activity of the PFC and the DA level in
the striatum would have a negative correlation, which is
consistent with experimental observations [18-21]. Inter-
estingly, the elevated DA levels in schizophrenic patients
were associated with the improvement of positive symp-
toms by antipsychotic medication [22].
Many antipsychotic drugs have been targeting dopamine
receptors, especially striatal D2 receptors [23]. Striatal
MSNs have D1, D2 and other subtypes of DA receptors
on the soma [24,25]. There are D2 receptors also at presy-
naptic terminals of the glutamatergic afferents from the
PFC [26,27] as well as on the dopaminergic fibers [26-28].
High densities of D2 receptors in the striatum would
enable DA to modulate powerfully the activity of the stria-
tal neurons and information flow through the striatum
[29]. It is suggested that DA gates the throughput of sen-
sorimotor and incentive motivational inputs to the stria-
tum and that DA is a “gatekeeper” for glutamate input to
the striatum [30]. In schizophrenic patients, striatal DA
turnover is elevated [31] and the baseline DA level in the
striatum is increased [22]. The elevated levels of DA
would overstimulate the D2 receptors in the striatum. The
D2 receptors on the glutamatergic terminals would sup-
press the glutamatergic input to the striatum from the
PFC, which may work as a DA filter of the input
[26,27,32]. On the other hand, the roles and effects of the
activation of DA receptors other than D2 receptors in the
corticostriatal system remain less unambiguous. The aim
of this article is to analyze how these D2 effects alter the
characteristics of the frontostriatal system in patients with
schizophrenia and healthy controls by using the receptor
binding theory and a circuit model of the frontostriatal
system. This article will also explore the possibility of the
computational approach in psychiatric research.
Methods
Receptor binding
Binding potential (BP) of D2 receptors is given by [33]
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The symbols used in the above equation and in the
following equations are listed in Table 1.
Drugs such as alpha-methyl-p-tyrosine (AMPT), a
competitive and reversible inhibitor of tyrosine
hydroxylase, reduce the extracellular concentration of
endogenous DA significantly [22,34]. Comparing the BP
before and after the administration of AMPT, we have
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for both schizophrenia patients and healthy controls.
In the above equation, we assumed that the D2 receptor
density, Bmax, did not change by acute administration of
AMPT. This has been confirmed in rats [34] but not in
humans. In schizophrenia patients, however, there is no
reason that the receptor density, Bmax,i st h es a m ew i t h
that of healthy controls. Therefore, we distinguish the
receptor density of schizophrenia patients (SZ) from
that of healthy controls (HC) by using Bmax, SZ and
Table 1 Symbols used in the model
a Coefficient that represents the presynaptic suppression of DA
release by the D2 autoreceptor
b Coefficient that represents the presynaptic depression of the
frontostriatal glutamatergic neurotransmission by D2 receptor
activation
Bmax relative D2 receptor density
BPAMPT Binding potential of the D2 receptor after DA depletion
[DA] Extracellular concentration of endogenous DA
[DA]
AMPT
Extracellular concentration of endogenous DA after depletion
F Free synaptic concentration of the administered antipsychotic
drug
f (x) Activation function: f (x) = tanh (x), x ≥ 0
KAPD Dissociation constant of the D2 receptor for the administered
antipsychotic drug
Kd Dissociation constant of the D2 receptor for the radiotracer
KDA Dissociation constant of the D2 receptors for endogenous DA
P D2 receptor occupancy by endogenous DA
PAPD D2 receptor occupancy by the administered antipsychotic drug
PDA
(APD)
D2 receptor occupancy by endogenous DA competing with
the administered antipsychotic drug
τd Time constant of the DA neurons
τs Time constant of the striatal neurons
τy Time constant of DA release
Vps Normalized connectivity coefficient of the frontostriatal
projection
Wdy Coefficient representing DA releasability
Wps Connectivity coefficient of the frontostriatal projection
Wsd Connectivity coefficient of the projection from the striatum to
the DA nuclei
xd Population activity of the midbrain DA nuclei
xp Population activity of the PFC
xs Population activity of the striatum
y DA release in the striatum: y =[ DA]
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concentration is different between patients and healthy
controls, which are denoted by [DA]SZ and [DA]HC,
respectively. The ratio of the BP of patients to that of
healthy controls is given by
BPSZ
BPHC
B SZ
B HC
KDA DA HC
KDA DA SZ



max,
max,
[]
[]
(3)
for both before and after AMPT. Here the dissociate
constant for DA, KDA, is also assumed to be unchanged
in schizophrenia patients. The occupancy of the D2
receptor by DA is given by
P
DA
KDA DA


[]
[]
(4)
Using BP data obtained from receptor imaging studies,
we are able to estimate the receptor occupancies for
both schizophrenia patients and healthy controls.
Circuit model
The circuit model consists of the three brain regions;
i.e., the PFC, the striatum, and the midbrain DA nuclei
such as the substantia nigra and the ventral tegmental
area (Fig. 1). It includes the effects of the stimulation
of D2 receptors at the glutamatergic terminals of the
frontostriatal projection and the autoreceptors on the
dopaminergic terminals in the striatum. The dynamics
of the population activities of the brain regions, the
DA release in the striatum, and D2 receptor occupancy
are given by
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The symbols used in the equations are also listed in
Table 1.
In the equilibrium state (d/dt = 0), we have
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Using the linear approximation of the activation
function f(x) ≈ x and introducing new variables:
Xp ≡ τsτdτyWpsWsd Wdy xp/KDA, Xs ≡ τdτyWsdWdy xs/KDA,
Xd ≡ τy Wdy xd/KDA, Jd ≡ τy Wdy Id/KDA,a n dY ≡ y/KDA,
we rewrite the above equations as
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From these equations, we have the relationships
between Xp and Xs as well as between Xp and Y as
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The variables have the physiological constraints that
all of them are positive (Xp, Xs, Xd, Y >0 )
Figure 1 Circuit diagram of the frontostriatal system.T h e
frontostriatal projection is glutamatergic (blue) and the axons from
the striatal neurons to the midbrain DA neurons are GABAergic
(red). D2 receptors are depicted at the terminals of the frontostriatal
axon and the dopaminergic fiber in the striatum. Dots around the
striatal neuron represent DA, which is released from the
dopaminergic fiber (yellow).
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The frontostriatal system
Figure 2 shows the relationships between Xp and Xs as
well as Xp and Y, which are given by Eq. (8), with five
different values of the D2 receptor activation coefficient
(b = 0, 0.25, 0.5, 0.75, 1.0). We assumed Jd =1f o rs i m -
plicity. The activation of the D2 receptor decreases Xs
and increases Y.A sar e s u l t ,t h eXs vs Xp curve is con-
vex downward and the Y vs Xp curve is convex upward
as shown in Fig. 2. The amount of the enhancement of
the DA release is generally large; it is 0.55 (b =1 . 0 )
compared to 0.30 (b = 0) when Xp = 0.7. That is, for the
modest activation of the PFC, the DA release increases
by 83% when the coefficient of the D2 receptor stimula-
tion increases from 0.0 to 1.0.
The effects of autoreceptor activation, which are
also given by Eq. (8), are depicted in Fig. 3. The
effect on the activity of the striatum, Xs, is small (Fig.
3a). The autoreceptor activation reduces the DA
release, and this effect is larger when the activity of
the PFC, Xp,b e c o m e sl o w e r( F i g .3 b ) .F o re x a m p l e ,
the amount of DA release is 0.30 without D2 hetero-
and autoreceptors, 0.55 with only the D2 heterorecep-
tor, and 0.50 with both the hetero- and autoreceptors
(Table 2).
Dopamine depletion
The occupancy of D2 receptors in the striatum was
estimated from the results of DA depletion studies
[22,34-38]. The estimated occupancies are summarized
in Table 3. There is only one study at present that
gives the occupancy in both healthy subjects and
schizophrenia patients [22]. The others studied either
schizophrenia patients or healthy subjects. Because
there is considerable variability in the occupancy
among studies, we here set two models as follows.
Model 1
The first model comes from the study [22]. The D2
receptor occupancy is estimated to be 12% in healthy
subjects and 21% in schizophrenia patients by assuming
the DA depletion of 70%. The relative value of the
D2 receptor density, Bmax, is also estimated to be 1.0 in
the healthy subjects and 1.2 in the patients. In this case,
the extracellular DA concentration normalized by the
dissociation constant, Y =[ DA]/KDA, is 0.136 in the
healthy subjects and 0.266 in the patients.
Model 2
The second model comes from averaging of the results
for healthy subjects because there are several different
studies from healthy subjects. The averaged D2 occu-
pancy is 23.6%. From the ratio of HC: SZ = 12%: 21% in
Model 1, this extrapolates to the D2 receptor occupancy
in patients of 23.6% × 21/12 = 41.3%. Model 2, there-
fore, uses the values of 24% and 41% for healthy subjects
and patients, respectively. The relative values of are
assumed to be the same with Model 1. In Model 2, the
extracellular DA concentration normalized by the disso-
ciation constant, Y =[ DA]/KDA, is 0.316 in healthy sub-
jects and 0.695 in schizophrenia patients. These results
are summarized in Table 4.
Schizophrenia patients vs healthy subjects
In this section, we compare the dependences of the glu-
tamatergic synaptic efficacy and the PFC activity on the
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Figure 2 Dependences of the striatal activity, Xs, and the normalized DA release, Y, on PFC activity, Xp. The D2 effects become larger for
higher values of b, the coefficient representing the presynaptic depression of the frontostriatal glutamatergic neurotransmission by D2 receptor
activation.
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and healthy subjects. Because the results will be differ-
ent between Model 1 and Model 2, we analyze them
one by one. From Eq. (9), the normalized frontostriatal
synaptic weight or the glutamatergic synaptic efficacy
and the PFC activity are given by
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And we have the differences of Vps and between
patients and healthy subjects as


Vb P b P b P b P
X
bP
P
Pa P
ps SZ HC HC SZ
p
      




11
1
1
1
11 () ( ) )
() ( )








 


 












 


 
SZ
HC bP
P
Pa P
1
1
1
11
(11)
Because Bmax = 1.0 (HC) vs 1.2 (SZ), the values of a
and b in patients should be 1.2 times of those in healthy
subjects. Both the differences given by Eq. (11) in Model
1 are depicted in Fig. 4. They are depicted against the
D2 receptor activation coefficient, b, with different
values of the autoreceptor activation coefficient, a.T h e
difference in the normalized frontostriatal synaptic
weight does not depend on the autoreceptor activation
coefficient as shown in Eq. (11) (Fig. 4a). On the other
hand, the PFC activity depends on the autoreceptor acti-
vation coefficient (Fig. 4b). Figure 5 shows the differ-
ences of the normalized frontostriatal synaptic weight
and the PFC activity between schizophrenia patients and
healthy subjects in Model 2.
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Figure 3 Effects of the activation of the D2 receptors on the striatal activity, Xs, and the normalized DA release, Y. The effect of the D2
autoreceptors on the dopaminergic fibers from the midbrain is specified by a. The effect of the D2 receptors on the glutamatergic terminals
from PFC pyramidal neurons is specified by b.
Table 2 Striatal population activity, Xs, and DA release,
Y, for different D2 effects (representing by the
coefficients of a and b) when the PFC is modestly
activated (Xp = 0.7)
a = 0 a = 0.2
b=0 b=1
Xs 0.7 0.45 0.46
Y 0.3 0.55 0.5
Table 3 Striatal D2 receptor occupancies estimated from
the receptor imaging studies
D2 occupancy
HC SZ References
12% 21% Abi-Dargham et al. (2000) [22]
45% - Erlandsson et al. (2003) [35]
26% - Laruelle et al. (1997) [34]
13% - Riccardi et al. (2008) [36]
22% - Verhoeff et al. (2001) [37]
- 16% Voruganti et al. (2001) [38]
average 23.6% -
There is only one study at present that gives the occupancy in both healthy
subjects and schizophrenia patients.
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The administration of an antipsychotic drug causes
competitive binding at D2 receptors. The occupancy of
the D2 receptor by endogenous DA under the existence
of an antipsychotic drug is given by
P
Y
KDA
Y
KDA
F
KAPD
DA APD () 
 1
(12)
The above equation shows that the occupancy of the
D2 receptor by endogenous DA is generally reduced by
the competitive binding with the antipsychotic drug.
Similarly, the occupancy of the D2 receptor by the
administered antipsychotic drug is given by
P
F
KASD
Y
KDA
F
KAPD
APD 
 1
(13)
We here assume that the optimum D2 antagonistic
effect of antipsychotic drugs is expected when the net
binding of endogenous DA to the D2 receptor in schizo-
phrenia patients is reduced to that in healthy controls,
that is
BP B P SZ DA APD SZ HC DA HC max, ( ), max, ,  (14)
or
P
B HC
B SZ
P DA APD SZ DA HC () , ,
max,
max,
 (15)
From Table 4, where PDA,HC is 12% in Model 1 and
24% in Model 2, the left hand side of the above equa-
tion is 10% in Model 1 and 20% in Model 2. Using
Eqs. (12) and (13) as well as the values of [DA]/KDA in
Table 4, we estimate the optimum free extracellular
concentration of the antipsychotic drug divided by the
dissociation constant and the occupancy of the D2
receptor by the administered antipsychotic drug as (Fopt/
KAPD,PAPD) = (1.39, 52.3%) in Model 1 and (1.78,
51.2%) in Model 2. The optimum antipsychotic effect
requires the dose of an administrating drug that is
higher in Model 2 than in Model 1. However, the
occupancy of the D2 receptor by the administered
drug is slightly lower in Model 2. This is because the
DA release in Model 2 is higher than in Model 1. The
t o t a lo c c u p a n c yb yD Aa n dt h ed r u g ,PDA(APD),SZ +
PAPD, is also higher in Model 2, which is 71.2% versus
62.3% in Model 1.
Table 4 Normalized D2 receptor densities, D2 receptor
occupancies by DA, and normalized extracellular DA
concentrations in healthy subjects (HC) and
schizophrenia patients (SZ) in Model 1 and Model 2
Model 1 Model 2
HC SZ HC SZ
Bmax 1 1.2 1 1.2
P 12% 21% 24% 41%
[DA]/KDA 0.136 0.266 0.316 0.695
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Figure 4 Differences of the normalized glutamatergic synaptic efficacy and the PFC activity between schizophrenia patients and
healthy subjects (i.e., those in SZ - those in HC), which are given by Eq. (11), in Model 1.
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A b i - D a r g h a me ta l .[ 2 2 ]c o n d ucted 6-week antipsycho-
tic medication of inpatients of schizophrenia (n =1 4 ) .
The drugs used were olanzapine (n =8 ) ,r i s p e r i d o n e
(n = 2), quetiapine (n = 2), clozapine (n = 1), and halo-
peridol (n = 1); benzodiazepine medications were
added as needed. They measured AMPT-induced
increases in D2 receptor BP before treatment and
PANSS scores one and six weeks after treatment. The
increase in D2 receptor BP induced by the acute
administration of AMPT into the patients had a signif-
icant positive correlation with the improvement of
positive symptoms after 6 weeks of the antipsychotic
treatment (R
2 = 0.58, p = 0.0015). Changes in negative
symptoms were not statistically significant. We have
estimated the D2 receptor occupancy from the BP
data. Our model describes the relationship between
PFC activity and D2 receptor binding: Eq. (10) relates
the PFC activity to the D2 receptor occupancy, which
is given by Eq. (4). The extracellular DA concentration
in Eq. (4) is obtained from Eq. (2) as
Y
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Using the assumption of a =0 . 3a n dt h eb values
from Fig. 3 of [22], the improvement of positive symp-
toms can be associated with the PFC activity, as shown
in Fig. 6. The regression model obtained from this
transformed data set is Δ PANSSp = 49.6 Xp -6 1 . 5
(R
2 =0 . 5 6 ,p = 0.002), where Δ PANSSp is the change
in the PANSS subscale for positive symptoms. This model
suggests that patients with lower PFC activity tend to have
greater improvement of positive symptoms following sub-
chronic (six weeks) antipsychotic treatment (note that
Δ PANSSp = 49.6 Xp - 61.5 < 0 for improvement).
Discussion
The model in this article describes the inverse relation-
ship between the PFC activity and the extracellular DA
level in the striatum. This inverse relationship is
accounted for by the circuitry of the frontostriatal sys-
tem with dopaminergic innervation. The circuitry is
consistent with anatomical study [39]. Functional neu-
roimaging studies [10,40] showing hypoactivation of
both the PFC and the striatum during task performance,
such as an oddball task and a working memory task, in
schizophrenia patients also support this circuit model.
Dysregulation of the frontostriatal system is responsible
for the deficits in cognitive functions, including execu-
tive functions, in schizophrenia patients [41,42]. This
article explored how much degree the circuit property
of the frontostriatal system, which links the regional
activities of the frontostriatal system and the striatal DA
function, is relevant to schizophrenia.
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Figure 5 Differences of the normalized glutamatergic synaptic efficacy and the PFC activity between schizophrenia patients and
healthy subjects (i.e., those in SZ - those in HC), which are given by Eq. (11), in Model 2.
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tors at the terminals of the frontostriatal projection
enhances the striatal DA level due to the suppression of
the glutamatergic input to GABAergic striatal neurons.
With this model, the amount of elevation of the striatal
DA level was estimated: When the PFC is modestly acti-
vated (Xp = 0.7 in this model), the amount of DA eleva-
tion is maximally 83% when assuming b = 1.0 (i.e., 1.83
times larger compared with the case of no D2 receptor
activation or b = 0). This elevation is reduced to 67%
when D2 autoreceptors on the dopaminergic terminals
are taken into account (assuming a = 0.2 in the model).
The DA level might further be enhanced with increased
proportions of the high-affinity states of D2 receptors,
though this has not been taken into account in the
model.
This study used receptor imaging data to estimate the
amount of the DA release in the striatum in schizophre-
nia patients and healthy subjects. The result was then
taken into the network model to calculate the glutama-
tergic input to the striatum and the population activity
of the striatal neurons. It was thus possible to assume
that the strength of D2 receptor activation is propor-
tional to the D2 receptor occupancy by DA rather than
the extracellular DA concentration. The combination of
this model and the published receptor imaging data of
schizophrenia patients and healthy controls enabled us
to compare PFC activity that accounted for the altera-
tions in the D2 receptor binding by endogenous DA in
the striatum. The results suggest that the PFC
population activity is reduced in schizophrenia patients,
which is consistent with the hypofrontality hypothesis.
Hypofrontality actually has unresolved issues; for exam-
ple, on glutamatergic and GABAergic neurotransmis-
sion. In this article, however, the term is used to
represent simply a reduction of the population activity
of the PFC. The estimated amount of the reduction of
the population activity depends on the D2 receptor
occupancy by DA, which varies largely across the studies
that have ever been made. Because the results of recep-
tor imaging studies have a large variability, this article
has chosen two model cases that could be representa-
tives of the results. The reason that Model 2 led to a
much larger difference in the PFC activity between
patients and controls is that the experimentally esti-
mated D2 receptor binding is higher than that in Model
1. Further accumulation of receptor imaging data would
make this estimation more precise.
We have estimated the ‘optimum’ D2 receptor occu-
pancy by an antipsychotic drug to be 52%. The estima-
tion of the optimum occupancy of an antipsychotic
drug is based on the assumption that the net binding
of endogenous DA to the D2 receptors should be the
same with that of healthy controls. Similar estimation
w a sm a d ep r e v i o u s l y[ 4 3 ] ,i nw h i c ht h ea u t h o r sm a d e
the assumption that the D2 receptor occupancy by DA
should be the same with that of healthy controls and
obtained the D2 receptor occupancy by an antipsycho-
tic drug of 48%. This is slightly lower than our estima-
tion because this estimation did not take the
upregulation of D2 receptors into account. It is inter-
esting to compare the estimated value of 52% with the
measured occupancies of various antipsychotic drugs
(Fig. 7 of [44]). The occupancies of many antipsychotic
drugs are higher than this level and mostly in the
range of 60-80%. The motor (extrapyramidal) side
effects become prominent when the occupancy exceeds
75-80% [45]. Unlike other drugs, clozapine and quetia-
pine have the occupancies in the striatum that are
mostly lower than 50%. The occupancy by quetiapine
is lower than the occupancy by clozapine [46]. Thera-
peutic effects of these drugs appear to be achieved at
the occupancy threshold that is lower than those of
other antipsychotic drugs [46]. For other drugs, the
occupancy should be lower than 75% to avoid extra-
pyramidal side effects. On the other hand, subjective
well-being appeared to have a negative correlation with
the striatal D2 receptor occupancy [47]. Therefore, the
D2 receptor occupancy by many of the antipsychotic
drugs should be in the range of 50-75% with a tradeoff
between the efficacy and subjective experience. Agid et
al. [23] examined the relationship between striatal and
extrastriatal D2 occupancies by antipsychotic drugs
and clinical effects, showing that striatal D2 occupancy
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Figure 6 Relationship between the change in the PANSS
subscale for positive symptoms and the PFC activity, Xp, when
(a, b) = (0, 0). The regression line is Δ PANSSp = 49.6 Xp - 61.5
(R
2 = 0.56, p = 0.002).
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Page 8 of 10predicted response in positive psychotic symptoms but
not negative symptoms and the prediction by striatal
D2 blockade was better than frontal, temporal, and
thalamic occupancy. Their result (Fig. 1 of [23]) shows
that striatal D2 blockade with the occupancy higher
than 50% has a practical therapeutic effect on positive
symptoms.
Schizophrenia patients with higher striatal D2 receptor
occupancy tended to have greater improvement of posi-
tive symptoms after antipsychotic treatments [22]. If the
hyperdopaminergic tone in the striatum is caused pri-
marily by PFC hypoactivity, this would further indicate
that hypofrontality could also be predictive of good
response of positive symptoms to antipsychotic medica-
tion. This article examined this predictability of the
model by using published data. The result shows that
patients with lower PFC activity have larger improve-
ments of positive symptoms as measured with PANSS
positive scores. Hypofrontality has been generally asso-
ciated with cognitive and negative symptoms in schizo-
phrenia [1-9]. By linking hypofrontality to striatal
hyperdopaminergic neurotransmission, the frontostriatal
model proposed in this article has associated hypofron-
tality with the therapeutic effect on positive symptoms.
This is testable by a combination of fMRI studies and
clinical studies. Furthermore, a multivariate analysis of a
data set from the combination of fMRI and PET recep-
tor imaging studies will test the frontostriatal model
more directly.
Conclusion
This article described theoretically the relationship
between regional activities in the frontostriatal system
and striatal DA release. These quantities were compared
between schizophrenia patients and healthy subjects by
using the results from receptor binding studies. The
results are consistent with hypofrontality. This study
also predicts that patients with lower PFC activity tend
to have greater improvement of positive symptoms fol-
lowing antipsychotic medication. The ‘optimum’ D2
receptor occupancy by antipsychotic drugs was esti-
mated to be 52%.
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